Summary
Pfizer Inc. filed its 10-Q for the period ending March 29, 1997, providing a snapshot of its financial performance during the first quarter of fiscal year 1997. The filing is primarily a procedural document and does not contain detailed financial statements or management discussion and analysis directly within the provided text. Investors should refer to the full 10-Q filing for comprehensive financial data, including revenue, profitability, cash flows, and any material changes or events impacting the company during the period. This report serves as a regulatory update on Pfizer's ongoing operations and financial standing.
Key Highlights
- 1Pfizer Inc. (PFE) filed its 10-Q quarterly report for the period ending March 29, 1997.
- 2The filing date was May 12, 1997, indicating timely reporting of quarterly performance.
- 3This report is a standard regulatory filing for public companies in the United States.
- 4The provided text is a directory listing from the SEC's EDGAR database, not the full financial report itself.
- 5Investors would need to access the actual 10-Q document (e.g., the .txt file mentioned) for detailed financial information.
- 6The filing indicates Pfizer was an active, reporting entity with ongoing operations in the first quarter of 1997.
Frequently Asked Questions
The primary purpose of this 10-Q filing is to provide the U.S. Securities and Exchange Commission (SEC) and the public with a standardized update on Pfizer Inc.'s financial performance and significant business events during the first quarter of fiscal year 1997. It's a regulatory requirement for publicly traded companies.
The provided text is a directory listing of the filing on the SEC's EDGAR system. To find the actual financial details, you would need to access and review the full 10-Q document, likely available as a .txt or HTML file through the SEC's EDGAR database search.
The provided directory listing does not contain specific financial figures such as revenue, net income, or earnings per share. A complete 10-Q filing would include detailed financial statements (income statement, balance sheet, cash flow statement) and accompanying notes, as well as Management's Discussion and Analysis (MD&A) of Financial Condition and Results of Operations.
The filing date of May 12, 1997, indicates that Pfizer submitted its quarterly report to the SEC within the mandated timeframe after the period ending March 29, 1997. This suggests compliance with SEC reporting regulations.